H D Shewade1,2, K S Shringarpure3, M Parmar4, N Patel3, S Kuriya3, S Shihora3, N Ninama3, N Gosai3, R Khokhariya3, C Popat3, H Thanki4, B Modi5, P Dave6, R K Baxi3, A M V Kumar1,2. 1. International Union Against Tuberculosis and Lung Disease, South-East Asia Office, New Delhi, India. 2. The Union, Paris, France. 3. Department of Preventive and Social Medicine, Medical College, Vadodara, India. 4. World Health Organization Country Office for India, New Delhi, India. 5. Department of Community Medicine, Gujarat Medical Education & Research Society Medical College and Hospital, Gandhinagar, India. 6. Department of Health and Family Welfare, Government of Gujarat, Gandhinagar, India.
Abstract
Setting: Gujarat, a state in west India. Background: Although treatment initiation has been improving among patients diagnosed with multidrug-resistant tuberculosis (MDR-TB) in programme settings, it has still not reached 100%. Objectives: To determine pre-treatment attrition (not initiated on treatment within 6 months of diagnosis), delay in treatment initiation (>7 days from diagnosis) and associated factors among MDR-TB patients diagnosed in 2014 in five selected districts served by two genotypic drug susceptibility testing (DST) facilities and a drug-resistant TB centre in Gujarat. Design: This was a retrospective cohort study involving record review. Results: Among 257 MDR-TB patients, pre-treatment attrition was seen in 20 (8%, 95%CI 5-12). Patients with 'follow-up sputum-positive' as their DST criterion and sputum smear microscopy status 'unknown' at the time of referral for DST were less likely to be initiated on treatment. The median delay to treatment initiation was 8 days (interquartile range 6-13). Patients referred for DST from medical colleges were more likely to face delays in treatment initiation. Conclusion: The Gujarat TB programme is performing well in initiating laboratory-confirmed MDR-TB patients on treatment. However, there is further scope for reducing delay.
Setting: Gujarat, a state in west India. Background: Although treatment initiation has been improving among patients diagnosed with multidrug-resistant tuberculosis (MDR-TB) in programme settings, it has still not reached 100%. Objectives: To determine pre-treatment attrition (not initiated on treatment within 6 months of diagnosis), delay in treatment initiation (>7 days from diagnosis) and associated factors among MDR-TB patients diagnosed in 2014 in five selected districts served by two genotypic drug susceptibility testing (DST) facilities and a drug-resistant TB centre in Gujarat. Design: This was a retrospective cohort study involving record review. Results: Among 257 MDR-TB patients, pre-treatment attrition was seen in 20 (8%, 95%CI 5-12). Patients with 'follow-up sputum-positive' as their DST criterion and sputum smear microscopy status 'unknown' at the time of referral for DST were less likely to be initiated on treatment. The median delay to treatment initiation was 8 days (interquartile range 6-13). Patients referred for DST from medical colleges were more likely to face delays in treatment initiation. Conclusion: The Gujarat TB programme is performing well in initiating laboratory-confirmed MDR-TB patients on treatment. However, there is further scope for reducing delay.
Entities:
Keywords:
India; initial loss to follow-up; multidrug-resistant tuberculosis; operational research; prevention and control
Authors: A D Harries; J Michongwe; T E Nyirenda; J R Kemp; S B Squire; A R Ramsay; P Godfrey-Faussett; F M Salaniponi Journal: Int J Tuberc Lung Dis Date: 2004-02 Impact factor: 2.373
Authors: H D Shewade; S Govindarajan; P Thekkur; C Palanivel; M Muthaiah; A M V Kumar; V Gupta; B N Sharath; J P Tripathy; K Vivekananda; G Roy Journal: Public Health Action Date: 2016-12-21
Authors: S K Sharma; B K Jha; A Sharma; V Sreenivas; V Upadhyay; C Jaisinghani; R Singla; H K Mishra; M Soneja Journal: Int J Tuberc Lung Dis Date: 2014-05 Impact factor: 2.373
Authors: Platon Eliseev; Grigory Balantcev; Elena Nikishova; Anastasia Gaida; Elena Bogdanova; Donald Enarson; Tara Ornstein; Anne Detjen; Russell Dacombe; Elena Gospodarevskaya; Patrick P J Phillips; Gillian Mann; Stephen Bertel Squire; Andrei Mariandyshev Journal: PLoS One Date: 2016-04-07 Impact factor: 3.240
Authors: Hemant Deepak Shewade; Dina Nair; Joel S Klinton; Malik Parmar; J Lavanya; Lakshmi Murali; Vivek Gupta; Jaya Prasad Tripathy; Soumya Swaminathan; Ajay M V Kumar Journal: J Epidemiol Glob Health Date: 2017-07-06